N
0.099
0.00 (0.00%)
| Penutupan Terdahulu | 0.099 |
| Buka | 0.099 |
| Jumlah Dagangan | 34,049 |
| Purata Dagangan (3B) | 166,339 |
| Modal Pasaran | 28,931,564 |
| Harga / Buku (P/B) | 5.26 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -149.07% |
| Margin Operasi (TTM) | -197.16% |
| EPS Cair (TTM) | -0.010 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -55.40% |
| Nisbah Semasa (MRQ) | 3.83 |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.09 M |
| Pulangan Atas Aset (ROA TTM) | -34.01% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | NOXOPHARM FPO [NOX] | - | - |
AISkor Stockmoo
-0.6
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.63 |
|
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 35.03% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |